HomeCompareORXOY vs VIG

ORXOY vs VIG: Dividend Comparison 2026

ORXOY yields 71.43% · VIG yields 1.61%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORXOY wins by $1.09M in total portfolio value
10 years
ORXOY
ORXOY
● Live price
71.43%
Share price
$2.80
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.12M
Annual income
$299,297.66
Full ORXOY calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.61%
Share price
$215.06
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.3K
Annual income
$175.21
Full VIG calculator →

Portfolio growth — ORXOY vs VIG

📍 ORXOY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORXOYVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORXOY + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORXOY pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORXOY
Annual income on $10K today (after 15% tax)
$6,071.43/yr
After 10yr DRIP, annual income (after tax)
$254,403.01/yr
VIG
Annual income on $10K today (after 15% tax)
$136.50/yr
After 10yr DRIP, annual income (after tax)
$148.93/yr
At 15% tax rate, ORXOY beats the other by $254,254.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORXOY + VIG for your $10,000?

ORXOY: 50%VIG: 50%
100% VIG50/50100% ORXOY
Portfolio after 10yr
$577.9K
Annual income
$149,736.43/yr
Blended yield
25.91%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORXOY buys
0
VIG buys
0
No recent congressional trades found for ORXOY or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORXOYVIG
Forward yield71.43%1.61%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1.12M$32.3K
Annual income after 10y$299,297.66$175.21
Total dividends collected$960.2K$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ORXOY vs VIG ($10,000, DRIP)

YearORXOY PortfolioORXOY Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$17,843$7,142.86$11,301$160.59+$6.5KORXOY
2$31,003$11,911.12$12,752$162.91+$18.3KORXOY
3$52,515$19,342.29$14,370$165.02+$38.1KORXOY
4$86,812$30,620.19$16,176$166.93+$70.6KORXOY
5$140,194$47,305.90$18,188$168.67+$122.0KORXOY
6$221,406$71,397.66$20,432$170.25+$201.0KORXOY
7$342,284$105,380.00$22,933$171.68+$319.4KORXOY
8$518,499$152,255.26$25,720$172.98+$492.8KORXOY
9$770,345$215,550.93$28,827$174.15+$741.5KORXOY
10$1,123,567$299,297.66$32,288$175.21+$1.09MORXOY

ORXOY vs VIG: Complete Analysis 2026

ORXOYStock

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Full ORXOY Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this ORXOY vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORXOY vs SCHDORXOY vs JEPIORXOY vs OORXOY vs KOORXOY vs MAINORXOY vs DGROORXOY vs NOBLORXOY vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.